Medicare Price Negotiation Will Disrupt Rebating In Part D; The Question Is How Much
Congressional Budget Office maps out how current rebating practices may change in Medicare Part D under the drug pricing provisions of the Inflation Reduction Act.
You may also be interested in...
PBMs are able to leverage brand-to-brand competition across a variety of drug classes to lower costs, but that achievement and the presence of me-too drugs is more complicated than what might on its surface look like a clear win for the US health system.
A focus on transparency, impacts of vertical integration and concerns about increasing government costs shows in the Congressional Budget Office score of the Senate pharmacy benefits manager reform bill.
The exemption could be sought for small molecule drugs covered by Medicare Part D that have high levels of spending and are marketed by large companies, the Pharmaceutical Care Management Association suggests.